United States Patent 12,442,000 (Imetelstat for Transfusion-Dependent Anemia in Myelodysplastic Syndrome): Claim Scope, Legal Coverage, and US Patent Landscape
Executive summary: US Patent 12,442,000 claims a method-of-treatment using intravenous (IV) infusion imetelstat for myelodysplastic syndrome (MDS) in a human with transfusion-dependent anemia, with claim-dependent scope covering every-4-weeks dosing, patients resistant or intolerant to prior non-telomerase inhibitor therapy, and administration with a pharmaceutically acceptable excipient, plus broader symptom-alleviation language. From a patent-landscape perspective, the estate’s practical strength is highest where it aligns with the clinical label and dosing schedule for imetelstat and where competitors attempt to introduce imetelstat for the same patient population via alternative regimens, routes, or combination strategies that could fall outside the claim limitations.
What does US Patent 12,442,000 claim for imetelstat in MDS?
Answer: The independent claim coverage is a specific clinical use: treating MDS by administering IV infusion imetelstat at a therapeutically effective amount to a human with transfusion-dependent anemia where the administration treats MDS. Dependent claims narrow to prior therapy resistance/intolerance (non-telomerase inhibitors), every four weeks dosing, and use of a pharmaceutically acceptable excipient. Additional claim coverage includes alleviating MDS symptoms, again tied to IV imetelstat.
Claim 1 scope (core independent method claim)
Claim 1 elements:
- Method for treating MDS in a human
- IV infusion of imetelstat
- Therapeutically effective amount
- Patient is transfusion-dependent anemia
- Administration is effective to treat MDS in the human
Scope implications
- Route-limitation is explicit (IV infusion). A non-IV route (if feasible) is a potential design-around axis.
- Patient phenotype is explicit (transfusion-dependent anemia). Claims likely do not cover MDS patients without this anemia phenotype.
- Causation/effect language (“effective to treat MDS”) is functional but tied to treatment efficacy. For litigation, it typically maps to clinical outcomes, but the infringement analysis still follows the claim’s stated limitations.
Claim 5 scope (independent claim with explicit schedule)
Claim 5 repeats the Claim 1 concept and adds:
- Administered every four weeks
Scope implications
- This is a second independent anchor with a dosing-frequency limitation. Even if a competitor uses IV imetelstat for the same population, dosing frequency could be an infringement trigger or an escape route depending on administration schedule and claim construction.
Claim 7 scope (symptom alleviation independent claim)
Claim 7:
- Alleviating at least one symptom associated with MDS
- Administer IV infusion imetelstat at a therapeutically effective amount
- Administration alleviates at least one MDS symptom
Scope implications
- This claim can capture endpoint-driven use even if the competitor disputes “treating MDS” as a regulatory or clinical construct. It is still constrained by IV administration, therapeutically effective amount, and the nexus to MDS symptoms.
- It does not explicitly retain the transfusion-dependent anemia limitation seen in Claims 1 and 5. It is therefore potentially broader on patient population, but it remains method-of-use constrained by “symptom associated with MDS.”
Do dependent claims add meaningful narrowing or new coverage?
Claim 2: resistant or intolerant to prior non-telomerase inhibitor-based therapy
Claim 2 adds a prior-treatment qualifier:
- Human is resistant or intolerant to prior non-telomerase inhibitor-based therapy
Coverage implications
- This is a clinically meaningful narrowing element that can reduce infringement exposure if a product is used only as a first-line or after a different class of therapy that is characterized as a “telomerase inhibitor-based” treatment (depending on construction).
- It also matters for label-aligned practice. If prescribing is limited to patients who failed non-telomerase inhibitor regimens, Claim 2 may align tightly with real-world use.
Claim 3: every four weeks dosing
Claim 3 narrows Claim 1 to:
- Therapeutically effective amount administered every four weeks
Coverage implications
- Creates a dosing-specific independent infringement hook. If a competitor shortens or lengthens intervals relative to every four weeks, they may avoid Claim 3/5, but could still face Claim 1/7 depending on dosing frequency interpretation and what “every four weeks” means in practice.
Claim 4 and Claim 6: pharmaceutically acceptable excipient
Claims 4 and 6 add:
- Administration includes a pharmaceutically acceptable excipient
Coverage implications
- This typically is a low-friction element. Most formulated IV drugs include excipients. If the claim is enforced as written, it is unlikely to be a meaningful design-around unless a competitor uses a materially different formulation that avoids typical excipient categorization (rare).
Claim 8: resistant or intolerant to prior non-telomerase inhibitor-based therapy
Claim 8 parallels Claim 2 but is dependent on Claim 7 (symptom alleviation):
- Same prior-therapy narrowing applies in the symptom alleviation context.
Coverage implications
- Useful where competitor practice targets symptom relief in specific refractory/intolerant segments.
Claim 9 and Claim 10: excipient and every four weeks
These mirror Claims 4 and 3 but in the symptom-alleviation dependent framework.
How does US Patent 12,442,000 likely read against alternative dosing, patient populations, and routes?
Route design-around
- The claims require IV infusion.
- A route that is not IV infusion (if any alternative exists in the imetelstat product space) is the most direct literal design-around axis.
Patient phenotype design-around
- Claims 1 and 5 require transfusion-dependent anemia.
- If a competitor targets non-transfusion-dependent MDS patients, they may reduce exposure for Claims 1/5 while still possibly facing Claim 7 (symptom alleviation).
Dosing schedule design-around
- Claims 3 and 5 require dosing every four weeks.
- If a competitor uses a different regimen (dose interval not “every four weeks”), it may avoid those dependent claim limitations, but not necessarily Claim 1 or Claim 7.
Indication vs symptom endpoint strategy
- Claim 1/5 require treatment of MDS.
- Claim 7 is keyed to alleviating MDS symptoms.
- A competitor attempting to frame use strictly as supportive care could still encounter infringement risk if the method aligns with “alleviates at least one symptom associated with MDS.”
Prior therapy qualifier strategy
- Claims 2 and 8 require resistance/intolerance to prior non-telomerase inhibitor-based therapy.
- If real-world use is restricted to different prior-treatment histories, these dependent claims may be less likely to be satisfied.
What patents typically sit around US Patent 12,442,000 in the US imetelstat estate?
Direct landscape analysis is constrained by the absence of patent-number metadata beyond the asserted claims. A complete US estate mapping requires the patent’s publication family links (application publication numbers), assignee, and priority data, plus the full list of related US patents and Orange Book/FDAs ties. The claim text indicates imetelstat and MDS treatment, but the required bibliographic anchor is not present here, so a full enumerated landscape cannot be produced without risking fabrication.
What can be stated from the claim structure alone is how typical imetelstat patent estates organize around:
- Drug substance/composition (active ingredient, salts, formulations)
- Delivery form (IV infusion formulation, excipients, stability)
- Method-of-use (specific disease, patient subtypes, dosing schedule)
- Patient selection / biomarkers / refractory criteria
- Combination regimens (if present in other family members)
Given that US 12,442,000 is framed as method-of-treatment, its strongest enforcement posture is against label-aligned imetelstat administration for MDS, especially when the prescribing follows:
- IV infusion
- transfusion-dependent anemia phenotype
- dosing interval approximating every four weeks
- refractory/intolerant history relative to non-telomerase inhibitor therapy
Which competitors face the highest generic or biosimilar entry risk for imetelstat under this claim set?
Answer limited to claim mechanics: Entry risk concentrates on any party that plans to market a product that is administered:
- IV infusion
- to transfusion-dependent anemia MDS patients (Claims 1/5)
- on dosing regimens that satisfy “every four weeks” (Claims 3/5)
- and, if pursuing the dependent claims, to refractory/intolerant patients after non-telomerase inhibitor-based therapy (Claims 2/8)
Why “IV infusion” matters
Even if a generic or authorized product contains the same active ingredient, infringement for method claims hinges on the claimed method performed. If the product is used off-label for non-IV administration or different patient subsets, the method claims may be harder to assert.
What Orange Book status or FDA regulatory posture matters for enforcing method claims here?
A complete Orange Book status review requires the exact NDA/BLA and listing records. No NDA/BLA identifiers are provided, so an Orange Book-specific, listing-by-listing status cannot be generated from the given inputs.
Key Takeaways
- US Patent 12,442,000 is a method-of-treatment patent centered on IV infusion imetelstat for MDS with transfusion-dependent anemia.
- Independent coverage:
- Claim 1: treating MDS with IV imetelstat in transfusion-dependent anemia patients.
- Claim 5: same, with every four weeks dosing.
- Claim 7: symptom alleviation using IV imetelstat (not explicitly limited to transfusion-dependent anemia).
- Dependent claims materially narrow by:
- refractory/intolerant history to prior non-telomerase inhibitor-based therapy (Claims 2, 8),
- every four weeks schedule (Claims 3, 5, 10),
- and excipient presence (Claims 4, 6, 9), which is generally not a strong design-around lever.
- The claim set’s most direct design-around axes are route (IV infusion) and patient phenotype (transfusion-dependent anemia), with dosing interval a secondary axis.
FAQs
-
Does Claim 7 cover MDS patients without transfusion-dependent anemia?
Claim 7 requires “alleviating at least one symptom associated with MDS” using IV imetelstat; it does not state transfusion-dependent anemia as an element.
-
Can a different dosing interval avoid infringement of the “every four weeks” claims?
Claims 3 and 5 require dosing every four weeks; a different interval could avoid those limitations, but Claim 1 and Claim 7 may still apply.
-
Is “pharmaceutically acceptable excipient” a practical design-around?
Generally no; most IV formulations include excipients, and this language usually does not distinguish a formulation enough for a credible carve-out.
-
How do “resistant or intolerant” and “non-telomerase inhibitor-based therapy” affect real-world enforcement?
Those terms add patient-history prerequisites that must be satisfied by the treated population in the alleged infringing use.
-
Does the patent protect combinations with other MDS drugs?
The claims provided focus on imetelstat administration as the therapeutic method; combination coverage would depend on whether other claims in the same patent family add combination regimen limitations.
References
- User-provided claim text for “United States Drug Patent 12,442,000” (no additional bibliographic sources supplied).
